These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9844616)

  • 1. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain.
    Citron ML; Kaplan R; Parris WC; Croghan MK; Herbst LH; Rosenbluth RJ; Reder RF; Slagle NS; Buckley BJ; Kaiko RF
    Cancer Invest; 1998; 16(8):562-71. PubMed ID: 9844616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.
    Kaplan R; Parris WC; Citron ML; Zhukovsky D; Reder RF; Buckley BJ; Kaiko RF
    J Clin Oncol; 1998 Oct; 16(10):3230-7. PubMed ID: 9779696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.
    Koizumi W; Toma H; Watanabe K; Katayama K; Kawahara M; Matsui K; Takiuchi H; Yoshino K; Araki N; Kodama K; Kimura H; Kono I; Hasegawa H; Hatanaka K; Hiraga K; Takeda F
    Jpn J Clin Oncol; 2004 Oct; 34(10):608-14. PubMed ID: 15591459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.
    Stambaugh JE; Reder RF; Stambaugh MD; Stambaugh H; Davis M
    J Clin Pharmacol; 2001 May; 41(5):500-6. PubMed ID: 11361046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
    Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
    Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
    Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
    Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
    Gabrail NY; Dvergsten C; Ahdieh H
    Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study.
    Parris WC; Johnson BW; Croghan MK; Moore MR; Khojasteh A; Reder RF; Kaiko RF; Buckley BJ
    J Pain Symptom Manage; 1998 Oct; 16(4):205-11. PubMed ID: 9803047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.
    Hale ME; Fleischmann R; Salzman R; Wild J; Iwan T; Swanton RE; Kaiko RF; Lacouture PG
    Clin J Pain; 1999 Sep; 15(3):179-83. PubMed ID: 10524470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
    Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
    J Opioid Manag; 2006; 2(3):155-66. PubMed ID: 17319449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
    Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
    J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet.
    Lux EA; Janecki M; Maritz MA
    Curr Med Res Opin; 2014 Nov; 30(11):2365-75. PubMed ID: 25050592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
    Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
    J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.
    Mandema JW; Kaiko RF; Oshlack B; Reder RF; Stanski DR
    Br J Clin Pharmacol; 1996 Dec; 42(6):747-56. PubMed ID: 8971431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.
    Roth SH; Fleischmann RM; Burch FX; Dietz F; Bockow B; Rapoport RJ; Rutstein J; Lacouture PG
    Arch Intern Med; 2000 Mar; 160(6):853-60. PubMed ID: 10737286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.
    Silvestri B; Bandieri E; Del Prete S; Ianniello GP; Micheletto G; Dambrosio M; Sabbatini G; Endrizzi L; Marra A; Aitini E; Calorio A; Garetto F; Nastasi G; Piantedosi F; Sidoti V; Spanu P
    Clin Drug Investig; 2008; 28(7):399-407. PubMed ID: 18544000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.